SEC Filing Summary: GRI Bio, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by GRI Bio, Inc. on August 20, 2025. The registrant is a Delaware corporation with its principal executive offices in La Jolla, California. The company's common stock trades on the Nasdaq Capital Market under the symbol "GRI." The filing is designated as an Emerging Growth Company.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure vehicle for a corporate presentation rather than a financial statement.
Material Changes
No material changes to financial position or operations are detailed in the text of this 8-K. The filing references the inclusion of a Corporate Presentation (Exhibit 99.1) dated August 20, 2025, which likely contains the substantive updates.
Guidance, Outlook, and Risks
Management commentary, guidance, and risk factors are not explicitly stated in the body of this filing. The document indicates that the information in Item 7.01 and Exhibit 99.1 is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Corporate Presentation) for the actual business updates and financial data referenced in this filing.
- Confirm the company's status as an Emerging Growth Company and any associated reporting exemptions.
- Note that the information provided in this specific 8-K is not subject to the liabilities of Section 18 of the Exchange Act.
- Verify the trading symbol "GRI" on the Nasdaq Capital Market for current market data.